Zim Laboratories Ltd Share Price

Pharmaceuticals - Indian - Bulk Drugs & Formln M/SNSE
₹147.80
-1.02-0.69% (1D)
As on 20 Nov 2026 at 15:50
As of 20 Nov 2026 at 15:50, Zim Laboratories Ltd is trading at ₹147.80. The 52-week range stands at ₹59.31–₹159.81, with a market cap of ₹793.88 crore. At a dividend yield of 0.00%, it is a small-cap stock in the Pharmaceuticals sector.

ZIMLAB Price Chart

Market Cap
₹793.88 Cr
PE Ratio
—
ROCE
3.83%

Zim Laboratories Ltd Performance

Zim Laboratories Ltd Fundamentals

Know More
Market Cap₹793.88 Cr
ROE0.54%
P/E Ratio (TTM)—
EPS (TTM)₹0.28
P/B Ratio2.82
Dividend Yield0.00%
Industry P/E91.72
Book Value₹52.52
Debt to Equity0.53
Face Value₹10

Zim Laboratories Ltd Shareholding Pattern

Know More
Promoter30.3%
Foreign Institutions0.2%
Mutual Funds1.2%
Domestic Institutions0%
Public68.3%

Zim Laboratories Ltd Financial Statements

Know More
No data for this view.

Zim Laboratories Ltd Peer Comparison

Know More
StocksLTP(₹)Market Cap(Cr)52 Week Low-High(₹)
Sun Pharmaceutical Industries Ltd
₹1,885.10
-14.90(-0.78%)
4,52,298.61,583.7 - 2,046.9
Torrent Pharmaceuticals Ltd
₹4,698.80
87.80(+1.90%)
1,78,727.33,672.3 - 5,250.0
Dr Reddys Laboratories Ltd
₹1,390.50
-10.40(-0.74%)
1,16,144.51,101.0 - 1,414.9
Cipla Ltd
₹1,414.95
-3.55(-0.25%)
1,14,312.11,165.7 - 1,539.7
Lupin Ltd
₹2,010.00
11.20(+0.56%)
91,915.91,892.9 - 2,529.5

About Zim Laboratories

Zim Laboratories Limited was incorporated in February, 1984 under the name and style of Zim Laboratories Private Limited in Maharashtra. The Company became a Public Limited Company through fresh Certificate of Incorporation issued by the Registrar of Companies, Mumbai. The Company commenced its operations in 1989 and is a specialist firm focused on the developing, manufacturing, and global distribution of differentiated generic Pharmaceutical and Nutraceutical products in oral solid dosage forms. The Company's comprehensive services include both PreFormulation Intermediates (PFI) and Finished Formulations (FF) across numerous vital therapeutic areas globally. Company's core therapeutic focus areas include: Urology, Gastrointestinal, NSAIDs / Analgesics, Anti-infectives, Cardiovascular, Central Nervous System, and Vitamins & Supplements. ZIM acts as a key supplier of both finished and semi-finished products within its targeted markets. ZIM operates three state-of-the-art manufacturing facilities i.e. General, Cephalosporin, and OTF and a well-established R&D centre, all staffed by highly skilled professionals. During the year 2019-20, ZIM Health Technologies Limited was acquired, making it a wholly owned subsidiary of the Company. SIA ZIM Laboratories Limited got incorporated as a wholly owned subsidiary in Latvia. In 2023, the Company launched Thinoral (Patented Oral Thin Film technology) as an alternate drug delivery platform across RoW/ Pharmerging Markets and EU. The Company entered into a joint venture with an Australian marketing company to launch New Innovative Products (NIP) and Oral Thin Films (OTF) in 2025. The OTF business marked a milestone with its first commercial order supplied in Europe for Sildenafil citrate 50 milligram ODS. The product was launched in Italy and Malta in 2025. During FY26, ZIM completed a total of 57 regulatory filings across key geographies, comprising 14 NIP filings, 29 OTF filings, and 14 FF filings. In line with the global expansion strategy, ZIM entered into strategic collaborations, including a partnership with a local UAE company to scale our Oral Thin Films (OTF) footprint across the GCC region during the year 2026.

Parent Organisation—
Founded1984
Managing Director—
NSE SymbolZIMLAB

Zim Laboratories Ltd Resistance and Support levels

R3173.01R2163.22R1157.16S1137.57S2131.51S3121.71147.80

Zim Laboratories Ltd Technicals

Current Price
₹147.80 ₹1.02 (-0.69%)
Bearish
0
Bullish
12
  • 20 Day7.0%
  • 50 Day9.4%
  • 100 Day16.1%
  • 200 Day28.9%

Zim Laboratories Ltd Latest News

View More
28 OCT 2026 | Wednesday
ZIM LABORATORIES LIMITED to review quarterly results at a board meeting November 4, 2026
08 OCT 2026 | Thursday
Zim Laboratories reports MUFG Intime India compliance confirmation for quarter ending September 2026
08 OCT 2026 | Thursday
CARE Ratings reaffirmed bank facilities for Zim Laboratories, citing a negative outlook on Rs 127.48 crore
28 SEPT 2026 | Monday
Zim Laboratories will restrict trading for insiders ahead of Q3 2026 results
18 SEPT 2026 | Friday
ZIM Laboratories establishes ZIM Laboratories SpA in Chile to grow its LATAM pharmaceutical business
15 SEPT 2026 | Tuesday
ZIM Laboratories FZE invested AED 916,000 in its subsidiary, ZIM Scientific Office LLC
31 JUL 2026 | Friday
ZIM LABORATORIES LIMITED to review quarterly results at a board meeting on August 6, 2026
06 JUN 2026 | Saturday
Zim Laboratories AGM scheduled

2026

Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Annual ResultRelease dateCheck Latest financial
Board MeetingAnnounced
Board MeetingAnnounced
Quarterly ResultRelease dateCheck Latest financial
Board MeetingAnnounced

Frequently asked questions

The share price of Zim Laboratories Ltd is ₹147.80 as of 20 Nov 2026 at 15:50.

Not sure where to start?

Book a free 30-minute consultation with our investment experts today!

Invest Now